- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 8, 2024Tara Sutton, Emily Tremblay Shortlisted for Euromoney’s Women in Business Law Awards
-
April 24, 2024IP Leadership Executive Summit
-
April 24, 2024IP Odyssey: Navigating the Latest Developments in Intellectual Property Law
-
April 30, 2024Navigating Generational Dynamics
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Torrent Pharmaceuticals Ltd. et al v. Daiichi Sankyo Co., Ltd., et al
Given the recent Supreme Court decisions concerning jurisdiction, general jurisdiction over branded drug company does not exist because branded company defends itself in prior litigation, and specific jurisdiction is not present when the branded drug company has limited contacts with the forum.
October 25, 2016
Case Name: Torrent Pharmaceuticals Ltd. et al v. Daiichi Sankyo Co., Ltd., et al, Civ. No. 16-C-2988, 2016 U.S. Dist. LEXIS 96448 (N.D. Ill. July 25, 2016) (Pallmeyer, J.)
Drug Product and Patent(s)-in-Suit: Benicar® (olmesartan medoxomil); U.S. Patent No. 6,878,703 (“the ’703 patent”)
Nature of the Case and Issue(s) Presented: This case concerns the issue of personal jurisdiction over defendant patent holders. Plaintiffs asserted that the court had either general or specific jurisdiction over the Defendants. Plaintiffs argued that general jurisdiction existed because Defendants were parties to a case before the court that was almost the same case as here, and never challenged jurisdiction in that case. Plaintiffs argued that specific jurisdiction existed based on various activities conducted by Defendants, such as obtaining the ’703 patent, licensing activities related to the ’703 patent, and that Defendants had employees in the jurisdiction, and conducted sales in the jurisdiction.
Defendants argued that general jurisdiction was not present because the law regarding the scope of general jurisdiction had significantly changed since the prior case. Under the current law, general jurisdiction did not exist. As to specific jurisdiction, Defendants argued that they had not performed any relevant activities in the jurisdiction in that Plaintiffs failed to identify any activities related to the enforcement of the ’703 patent in this jurisdiction. The court found that it lacked personal jurisdiction over Defendants.
Why Defendants Prevailed: The court found that it lacked general jurisdiction over Defendants because the case law had changed. In particular, the court found that the Supreme Court in Daimler AG v. Bauman had significantly reduced the scope of general jurisdiction to cases in which a defendant was incorporated or had its principal place of business within that district. The court rejected Plaintiffs’ argument that Defendants had waived or acquiesced to general jurisdiction by defending themselves in a similar case because those actions of defending oneself were not “purposefully availing” oneself of the benefits of the forum.
As to specific jurisdiction, the court firstly determined which activities were relevant to the analysis. Where the patent holder was the defendant, the court found that only activities related to the enforcement or defense of validity in the forum were relevant to the issue of specific jurisdiction. As such, Defendants’ sales activities and number of employees within the jurisdiction were irrelevant. Plaintiffs only alleged that Defendants had conducted “licensing activities” in the forum, which the court found to be too vague to establish specific jurisdiction. Lastly, the court noted that its analysis would be different in the scenario were the ANDA filer the defendant, but that the Federal Circuit does not require the analysis to be the same when the branded drug manufacturer is the defendant.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.